John Wrangle to Antineoplastic Agents, Immunological
This is a "connection" page, showing publications John Wrangle has written about Antineoplastic Agents, Immunological.
Connection Strength
0.776
-
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018 05; 19(5):694-704.
Score: 0.558
-
The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine. Cancer. 2018 04 15; 124(8):1650-1659.
Score: 0.137
-
Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. Cell Rep Med. 2021 10 19; 2(10):100426.
Score: 0.045
-
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma. Clin Cancer Res. 2018 11 01; 24(21):5250-5260.
Score: 0.036